Dossier assessment

Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-153
Last updated

Report documents

  1. Extract of dossier assessment

    Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 264 kB, DE, not accessible
  2. Dossier assessment

    Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 580 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-153

Drug assessment at a glance

  1. Drug assessment at a glance

    Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 205 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A25-153
Commission
Commission awarded on 15.12.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-153

Connected Projects

  1. Dossier assessment

    Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-47
    Last updated

    Status: Commission completed

  2. Addendum

    Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48

    Project no.
    A23-98
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-90
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form